Whether targeting IL11 in rare human genetic disease offers an approach for disease mitigation, beyond gene therapy, is unknown but POC in animal models of Alport and Marfan syndrome suggests this premise may be worth testing in clinical trials. Here, IL11 is linked to hereditary disease.